

Box Seq

A

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DEX-0054

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**NOVEL MUTATIONS IN HUMAN MLH1 AND HUMAN MSH2 GENES USEFUL IN DIAGNOSING
COLORECTAL CANCER**

and invented by:

Robbins et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 30 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

OCT 27 1999
JC520 U.S. PTO
09/426548

10/22/99

RECEIVED
OCT 27 1999
OIFE/JCWS

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DEX-0054

Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets _____
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☒ Paper Copy
- b. ☒ Computer Readable Copy (identical to computer copy)
- c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EL429958222US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DEX-0054

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16. ☐ Additional Enclosures *(please identify below):*

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	8	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	5	- 3 =	2	x \$78.00	\$156.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$760.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$916.00

- ☒ A check in the amount of **\$916.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **12-1086** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Jane Massey Licata

Signature

Jane Massey Licata
Reg. No. 32,257
Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, NJ 08053
Tel: 856-810-1515
Fax: 856-810-1454

Dated: **October 22, 1999**

CC:

DEX-0054

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No.EL429958222US

Date of Deposit OCTOBER 22, 1999

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 30 pages of Specification, including two (2) pages of Claims, and one (1) page of Abstract;
- 3) Unexecuted Declaration and Power of Attorney.
- 4) Statement to Support Filing and Submission in Accordance with 37 CRF §§1.821-1.825;
- 5) Sequence Listing;
- 6) Diskette containing computer readable copy of Sequence Listing;
- 7) Return Post Card; and
- 8) Check in the amount of \$916.00.

Jane Massey Licata
JANE MASSEY LICATA

**NOVEL MUTATIONS IN HUMAN MLH1 AND HUMAN MSH2 GENES USEFUL
IN DIAGNOSING COLORECTAL CANCER**

INTRODUCTION

This application claims the benefit of U.S. provisional
5 application Serial No. 60/105,180, filed October 22, 1998.

BACKGROUND OF THE INVENTION

Colorectal cancer (CRC) is one of the most common fatal
cancers in developed countries, and the worldwide incidence
is increasing. The United States and the United Kingdom are
10 high incidence countries, with an estimated 133,500 new cases
and 55,300 deaths (Parker et al. CA Cancer J. Clin. 1996 46:5-
27) in the United States and 30,941 cases and approximately
17,000 deaths in the United Kingdom (HMSO UK Cancer Registry
Data). The population lifetime risk is 1 in 25 in the United
15 States and Northern Europe and thus represents a significant
public health issue (Sharp et al. Cancer Registration
Statistics Scotland 1981-1990, Information and Statistics
Division, The National Health Service in Scotland, Edinburgh
(1993)). Identification of people who are predisposed to the
20 disease would allow targeting of effective preventative
measures with the aim of reducing the considerable cancer
related mortality (Burke et al. J. Am. Med. Ass'n. 1997
227:915-919).

One group of people with a very high colorectal cancer
25 risk are those who carry germline mutations in genes that
participate in DNA mismatch repair. hMSH2 (Fishel et al. Cell
1993 75:1027-1038; Leach et al. Cell 1993 75:1215-1225; U.S.
Patent 5,591,826) and hMLH1 (Bronner et al. Nature 1994
368:258-261; Papadopoulos et al. Science 1994 263:1625-1629;

PCT Publication No. WO 95/20678, published on August 3, 1995) are the two genes most commonly involved in heredity predisposition to CRC, but mutations in hPMS1 and hPMS2 also occur in a minority of cases (Nicolaidis et al. Nature 1994 5 371:75-80). Such mutations are usually associated with marked familial aggregation of colorectal, uterine and other cancers constituting the clinically defined autosomal dominant syndrome of hereditary non-polyposis colorectal cancer (HNPCC) (Lynch et al. Gastroenterology 1993 104:1535-1549; Liu et al. 10 Nature Med. 1996 2:169-174; Wijnen et al. Am. J. Hum. Genet. 1995 56:1060-1066; Mary et al. Hum. Mol. Genet. 1994 3:2067-2069; Nystrom-Lahti et al. Nature Med. 1995 1:1203-1206). However, an appreciable proportion of patients who have early onset colorectal cancer but who do not fulfill pragmatic 15 criteria for HNPCC (Vasen et al. Dis. Colon Rectum 1991 34:424-425) also carry mismatch repair gene mutations (Liu et al. Nature Med. 1995 2:169-174; Dunlop et al. Br. Med. J. 1997 314:1779-1780). Thus, restricting genetic testing to individuals from families fulfilling HNPCC criteria is likely 20 to exclude a significant fraction of gene carriers in the general population. However, screening unselected patients with sporadic cancer represents an enormous workload and may provide a very low yield of mutation carriers (Liu et al. Nat. Med. 1995 1:348-352; Tomlinson et al. J. Med. Genet. 1997 25 34:39-42).

It is clear that issues concerning indications for genetic testing and interpretation of results are critical in hereditary cancer syndromes (Giardiello et al. N. Engl. J. Med. 1997 336: 823-827).

30 Using a population-based approach, factors indicative of the likelihood of identifying patients with mismatch repair gene mutations were investigated. Improved approaches to mutation detection and the prevalence of detectable mismatch repair gene alterations in various screened groups who were

not selected on the basis of family history were also determined.

SUMMARY OF THE INVENTION

An object of the present invention is to provide novel,
5 variant hMLH1 sequences.

Another object of the present invention is to provide novel, variant hMSH2 sequences.

Another object of the present invention is to provide a method of diagnosing hereditary non-polyposis colorectal
10 cancer in a patient or determining a patient's susceptibility to developing hereditary non-polyposis colorectal cancer via detection of novel variant hMLH1 or hMSH2 sequences or the exonic or intronic sequences of the hMLH1 and hMSH2 genes.

Another object of this invention is to provide methods
15 and compositions for identifying new variants of hMLH1 and hMSH2 genes.

Yet another object of the present invention is to provide experimental models of hereditary non-polyposis colorectal cancer.

20 DETAILED DESCRIPTION OF THE INVENTION

To better elucidate the structure of human MLH1 and human MSH2 genes and to determine possible sites of alternative splicing, the genes were cloned and sequenced and PCR was used to determine alternate splice products (variants)
25 and exon/intron boundaries. Elucidation of intron/exon boundary sequences revealed that hMLH1 is encoded by 19 coding exons. The hMLH1 gene sequence was determined by PCR.

The intron/exon structure of the hMLH1 is shown below. Positions of introns that interrupt the hMLH1 cDNA are shown.
30 Exonic sequence is presented in upper case and intronic sequence in lower case letters. Exons are numbered from the 5' end of the cDNA sequence.

hMLH1 Exon 1aggcactgaggtgattggc (SEQ ID NO:1)

tgaaggcacttccgttgagcatctagacgtttccttggctcttctggcgccaaa (SEQ ID NO:2)

5 ATGTCGTTTCGTGGCAGGGGTTATTCGGCGGCTGGACGAGACAGTGGTGAACCGCATCGC
GGCGGGGAAGTTATCCAGCGGCCAGCTAATGCTATCAAAGAGATGATTGAGAACTG (SEQ ID NO:3)

gtacggagggagtcgagccgg (SEQ ID NO:4)

gctcacttaagggctacga (SEQ ID NO:5)

10 cttaacgg (SEQ ID NO:6)

hMLH1 Exon 2aatatgtacattagagtagttg (SEQ ID NO:7)

cagactgataaattattttctgtttgatttgccag (SEQ ID NO:8)

TTTAGATGCAAAATCCACAAGTATTCAAGTGATTGTTAAAGAGGGAGGCCTGAAGTTGA

15 TTCAGATCCAAGACAATGGCACCGGGATCAGG (SEQ ID NO:9)

gtaagtaaaacctcaaagtagcaggatgtttgtgcgcttcatggaa (SEQ ID NO:10)

gagtcaggaccttttctctg (SEQ ID NO:11)**hMLH1 Exon 3**agagatttggaatgagtaac (SEQ ID NO:12)

20 atgattatttactcatctttttggtatctaacag (SEQ ID NO:13)

AAAGAAGATCTGGATATTGTATGTGAAAGGTTCACTACTAGTAACTGCAGTC

CTTTGAGGATTTAGCCAGTATTTCTACCTATGGCTTTTCGAGGTGAG (SEQ ID NO:14)

gtaagctaaagattcaagaaatgtgtaaaatat (SEQ ID NO:15)

cctcctgtgatgacattgt (SEQ ID NO:16)

25 c

hMLH1 Exon 4aacctttccctttggtgagg (SEQ ID NO:17)tgacagtgggtgaccagcagtgagtttttctttcagtcctattttcttttcttccttag
(SEQ ID NO:18)30 GCTTTGGCCAGCATAAGCCATGTGGCTCATGTTACTATTACAACGAAAACAGCT
GATGGAAAGTGTGCATACAG (SEQ ID NO:19)

gtatagtgtgctgacttctttttactcatatatatttcattctgaaatgtatttttg (SEQ ID NO:20)

gcctaggtctcagagtaatc (SEQ ID NO:21)

hMLH1 Exon 5

5 ttgatat (SEQ ID NO: 22)

gattttctctttttccccttggg (SEQ ID NO:23)

attagtatctatctctctactggatattaatttggttatattttctcattag (SEQ ID NO: 24)

AGCAAGTTACTCAGATGGAAAAGTAAAGCCCCCTCCTAAACCATGTGCTGGCAATCAAG

10 GGACCCAGATCACG (SEQ ID NO: 25)

gtaagaatggtacatgggaca (SEQ ID NO:26)

gtaaattgttgaagctttgtttg (SEQ ID NO:27)

hMLH1 Exon 6

gggttttattttcaagtacttctatg (SEQ ID NO: 28)

15 aattttacaagaaaaatcaatcttctgttcag (SEQ ID NO: 29)

GTGGAGGACCTTTTTTACAACATAGCCACGAGGAGAAAAGCTTTAAAAAATCCAAGT

GAAGAATATGGGAAAATTTTGAAGTTGTTGGCAG (SEQ ID NO:30)

gtacagtcctcaaatctgggagtggtctctgagatttgtcatcaaagtaatgtgttctagt
(SEQ ID NO:31)

20 gctcatatcattgaacagttgctgagc (SEQ ID NO:32)

hMLH1 Exon 7

ctagtgtgtgtttttggc (SEQ ID NO:33)

aactctttttcttactctttttgtttttctttttccag (SEQ ID NO:34)

GTATTCAGTACACAATGCAGGCATTAGTTTCTCAGTTAAAAAA (SEQ ID NO:35)

25 gtaagttcttggttttatgggggatggttttggttttatgaaaagaaaaaaggggattttt
aatagtttgct (SEQ ID NO:36)

ggaggagataagggttatg (SEQ ID NO:37)

hMLH1 Exon 8

ctcagccatgagacaataaatcc (SEQ ID NO:38)

30 ttgtgtcttctgctgtttgtttatcag (SEQ ID NO:39)

CAAGGAGAGACAGTAGCTGATGTTAGGACACTACCCAATGCCTCAACCGTGGACAATAT
TCGCTCCATCTTTGGAAATGCTGTTAGTCG (SEQ ID NO:40)
gtatgtcgataacctatataaaaaaatcttttacatttattatcttggtttatcatt (SEQ
ID NO:41)

5 ccatcacattatttgggaacc (SEQ ID NO: 42)

hMLH1 Exon 9

caaaagcttcagaatctc (SEQ ID NO: 43)

ttttctaataag (SEQ ID NO:44)

AGAACTGATAGAAATTGGATGTGAGGATAAAACCCTAGCCTTCAAATGAATGGTTACA
10 TATCCAATGCAAACACTACTCAGTGAAGAAGTGCATCTTCTTACTCTTCATCAACC (SEQ
ID NO:45)

gtaagttaaaaagaaccacatgggaaat (SEQ ID NO:46)

ccactcacaggaaacacccacag (SEQ ID NO:47)

hMLH1 Exon 10

15 catgacttttgtgtgaatgtacacc (SEQ ID NO: 48)

tgtgacctcaccctcaggacagttttgaaactggttgctttctttttattgttttag (SEQ
ID NO:49)

ATCGTCTGGTAGAATCAACTTCCTTGAGAAAAGCCATAGAAACAGTGTATGCAGCCTATT
TGCCCCAAAACACACACCCATTCCTGTACCTCAG (SEQ ID NO:50)

20 gtaatgtagcaccaaactcctcaaccaagactcacaaggaa (SEQ ID NO:51)

cagatgtttctatcaggctctcctc (SEQ ID NO: 52)

hMLH1 Exon 11

gggctttttctccccctccc (SEQ ID NO:53)

actatctaaggtaattgttctctcttattttcctgacag (SEQ ID NO: 54)

25 TTAGAAATCAGTCCCCAGAATGTGGATGTTAATGTGCACCCACAAAGCATGAAG
TTCACTTCCTGCACGAGGAGAGCATCCTGGAGCGGGTGCAGCAGCACATCGAGAGCAAG
CTCCTGGGCTCCAATTCCTCCAGGATGTACTTCACCCAG (SEQ ID NO:55)

gtcagggcgctttctcatccagctacttctctggggcctttgaaatgtgcccggccaga
(SEQ ID NO:56)

30 cgtgagagcccagatttt (SEQ ID NO:57)

hMLH1 Exon 12aattatacctcatactagc (SEQ ID NO:58)ttctttcttagtactgctccatttggggacctgtatatctatacttcttattctgagtct
ctccactatatatatatatatatatatattttttttttttttttttttttaatacag (SEQ

5 ID NO:59)

ACTTTGCTACCAGGACTTGCTGGCCCCCTCTGGGGAGATGGTTAAATCCACAACAAGTCT
GACCTCGTCTTCTACTTCTGGAAGTAGTGATAAGGTCTATGCCACCAGATGGTTCGTA
CAGATTCCCGGGAACAGAAGCTTGATGCATTTCTGCAGCCTCTGAGCAAACCCC
TGTCCAGTCAGCCCCAGGCCATTGTACAGAGGATAAGACAGATATTTCTAGTGGCAGGG10 CTAGGCAGCAAGATGAGGAGATGCTTGAACCTCCAGCCCCCTGCTGAAGTGGCTGCCAAAA
ATCAGAGCTTGGAGGGGGATACAACAAAGGGGACTTCAGAAATGTCAGAGAAGAGAGGAC
CTACTTCCAGCAACCCAG (SEQ ID NO:60)

gtatggccttttgggaaaagtacagccta (SEQ ID NO:61)

cctcctttattctgtaataaaac (SEQ ID NO:62)15 **hMLH1 Exon 13**tgcaacccacaaaatttggc (SEQ ID NO:63)taagtttaaaaaacaagaataataatgatctgcacttccttttcttcattgcag (SEQ ID
NO:64)

AAAGAGACATCGGGAAGATTCTGATGTGGAAATGGTGGGAAGATGATTCCCGAAAGGAAA

20 TGA CTGCAGCTTGTACCCCCGGAGAAGGATCATTAACCTCACTAGTGTTTTGAGTCTCCAG
GAAGAAATTAATGAGCAGGGACATGAGG (SEQ ID NO:65)gtacgtaaacgctgtggcctgcctgggatgcatagggcctcaactgcaa (SEQ ID NO:
66)ggttttggaaatggagaaaag (SEQ ID NO:67)25 **hMLH1 Exon 14**tggtgtctctagttctgg (SEQ ID NO: 68)tgcttggtgcttttggatcaatgaagtggggttggtaggattctattacttacctgttttt
tggtttttattttttgttttgcag (SEQ ID NO:69)

TTCTCCGGGAGATGTTGCATAACCACTCCTTCGTGGGCTGTGTGAATCCTCAGTGGGCCTTG

30 GCACAGCATCAAACCAAGTTATACCTTCTCAACACCACCAAGCTTAG (SEQ ID NO:70)

gtaaatacagctgagtgtgtgaacaa (SEQ ID NO:71)

gcagagctactacaacaatg (SEQ ID NO: 72)

hMLH1 Exon 15

cccatttgtcccaactgg SEQ ID NO:73

ttgtatctcaagcatgaattcagcttttccttaaagtcacttcatttttattttcag (SEQ ID NO:74)

5 TGAAGAACTGTTCTACCAGATACTCATTTATGATTTTGCCAATTTTGGTGTTCTCAGGTTATCG (SEQ ID NO:75)

gtaagtttagatccttttcactt (SEQ ID NO:76)

ctgacatttcaactgaccg (SEQ ID NO:77)

hMLH1 Exon 16

10 catttggatgctccgttaaagc (SEQ ID NO:78)

ttgtccttcatgttcttgcttcttcctag (SEQ ID NO:79)

GAGCCAGCACCGCTCTTTGACCTTGCCATGCTTGCCCTAGATAGTCCAGAGAGTGGCTG
GACAGAGGAAGATGGTCCCAAAGAAGGACTTGCTGAATACATTGTTGAGTTTCTGAAGA
AGAAGGCTGAGATGCTTGCACTATTCTCTTTGGAAATTGATGAG (SEQ ID NO:80)

15 gtgtgacagccattcttatacttctgttgattctc (SEQ ID NO:81)

caaataaaatttccagccgggtg (SEQ ID NO:82)

hMLH1 Exon 17

ggaaaggcactggagaaatggg (SEQ ID NO:83)

atttgtttaaactatgacagcattatttcttgttcccttgctcctttttcctgcaagcag

20 (SEQ ID NO:84)

GAAGGGAACCTGATTGGATTACCCCTTCTGATTGACAACTATGTGCCCCCTTTGGAGGG
ACTGCCTATCTTCATTCTTCGACTAGCCACTGAG (SEQ ID NO:85)

gtcagtgatcaagcagataactaagcattt (SEQ ID NO:86)

cggtacatgcatgtgtgctggaggg (SEQ ID NO:87)

25 **hMLH1 Exon 18**

taagtagtctgtgatctccg (SEQ ID NO:88)

tttagaatgagaatgtttaaattcgtacctattttgaggtattgaatttctttggaccag
(SEQ ID NO:89)

GTGAATTGGGACGAAGAAAAGGAATGTTTTGAAAGCCTCAGTAAAGAATGCGCTATGTT

30 CTATTCCATCCGGAAGCAGTACATATCTGAGGAGTCGACCCTCTCAGGCCAGCAG (SEQ ID NO:90)

gtacagtggatgatgcacactggcaccacaggacta (SEQ ID NO:91)

ggacaggacctcatat (SEQ ID NO:92)

hMLH1 Exon 19

gacaccagtgtatgttgg (SEQ ID NO:93)

5 gatgcaaacagggaggcttatgacatctaattgtgttttccag (SEQ ID NO:94)

AGTGAAGTGCCTGGCTCCATTCCAAACTCCTGGAAGTGGACTGTGGAACACATTGTC

TATAAAGCCTTGCGCTCACACATTCTGCCTCCTAAACATTTACAGAAGATGGAAATATC

CTGCAGCTTGCTAACCTGCCTGATCTATACAAAGTCTTTGAGAGGTGTTAA (SEQ ID NO:95)

10 atatggttatttatgcactgt (SEQ ID NO:96)

gggatgtgttcttctttctc (SEQ ID NO:97)

tgtattccgatacaaagtgttgtatcaaagtgtgatatacaaagtgtaccaacataagtg
(SEQ ID NO:98)

Elucidation of intron/exon boundary sequences revealed
15 that hMSH2 is encoded by 16 coding exons. The hMSH2 gene
sequence was determined by PCR.

The intron/exon structure of the hMSH2 is shown below.
Positions of introns that interrupt the hMSH2 cDNA are shown.
Exonic sequence is presented in upper case and intronic
20 sequence in lower case letters. Exons are numbered from the
5' end of the cDNA sequence.

hMSH2 Exon 1

ggcgggaaacagcttagtggtgtggggtcg (SEQ ID NO:99)

cgcattttcttcaaccagga (SEQ ID NO:100)

25 ggtgaggaggttttcgac (SEQ ID NO:101)

ATGGCGGTGCAGCCGAAGGAGACGCTGCAGTTGGAGAGCGCGGCCGAGGTCGGCTTCGTG

CGCTTCTTTTCAGGGCATGCCGAGAAGCCGACCACAGTGCGCCTTTTCGACCGGGG

CGACTTCTATACGGCGCACGGCGAGGACGCGCTGCTGGCCGCCCAGGAGGTGTTCAAGA

CCCAGGGGGTGATCAAGTACATGGGGCCGGCAG (SEQ ID NO:102)

30 gtgagggccgggac (SEQ ID NO:103)

ggcgctgctggggagg (SEQ ID NO:104)

gac

hMSH2 Exon 2

gaa

gtccagctaatacacagtgccttg (SEQ ID NO:105)

aacatgtaatatctcaaactctgtaatgtactttttttttttttaag (SEQ ID NO:106)

5 GAGCAAAGAATCTGCAGAGTGTTGTGCTTAGTAAATGAATTTTGAATCTTTTGTA
GATCTTCTTCTGGTTCGTCAGTATAGAGTTGAAGTTTATAAGAATAGAGCTGGAAATAAG
GCATCCAAGGAGAATGATTGGTATTTGGCATATAAG (SEQ ID NO:107)

gtaattatcttcctttttaatttacttattttt (SEQ ID NO:108)

ttaagagtagaaaaataaaaaatgtg (SEQ ID NO:109)

10 aag

hMSH2 Exon 3

ATTAATAAGGtTCATAGAGTTTGGATTTTTCctTTTtgc (SEQ ID NO:110)

ttataaaaatttttaaaagtatgttcaag (SEQ ID NO:111)

agtttggttaaatttttaaaaatttttatttttacttag (SEQ ID NO:112)

15 GCTTCTCCTGGCAATCTCTCTCAGTTTGAAGACATTCTCTTTGGTAACAATGAT
ATGTCAGCTTCCATTGGTGTGTGGGTGTTAAAATGTCCGCAGTTGATGGCCAGAGACAG
GTTGGAGTTGGGTATGTGGATTCCATACAGAGGAACTAGGACTGTGTGAATTCCTGAT
AATGATCAGTTCTCCAATCTTGAGGCTCTCCTCATCCAGATTGGACCAAAGGAATGTGT
TTTACCCGGAGGAGAGACTGCTGGAGACATGGGGAACTGAGACAG (SEQ ID NO:113)

20 gtaagcaaattgagtcttagtgat (SEQ ID NO:114)

agaggagattccaggcctaggaaaag (SEQ ID NO:115)

gc

TCTTTAATTGACATGATACTG (SEQ ID NO:116)

hMSH2 Exon 4

25 ttca

tttttgctttttcttattccttttc (SEQ ID NO:117)

tcatagtagtttaaaactatttctttcaaaatag (SEQ ID NO:118)

ATAATTCAAAGAGGAGGAATTCTGATCACAGAAAGAAAAAAGCTGACTTTTCCACAAA
AGACATTTATCAGGACCTCAACCGGTTGTTGAAAGGCCAAAAGGGAGAGCAGATGAATA

30 GTGCTGTATTGCCAGAAATGGAGAATCAG (SEQ ID NO:119)

gtacatggattataaatgtgaattacaatatataatgtaaatatgtaatatataata
aataatatgtaaactatagtgacttt (SEQ ID NO:120)
ttagaaggatatttctgtca (SEQ ID NO:121)
tat

5 **hMSH2 Exon 5**

actggcacca (SEQ ID NO:122)
gtggtatagaaatcttcgattttt (SEQ ID NO:123)
aaattccttaatttttag (SEQ ID NO:124)
GTTGCAGTTTCATCACTGTCTGCGGTAATCAAGTTTTTAGAACTCTTATCAGATGATTC
10 CAACCTTTGGACAGTTTGAAGTACTACTTTTGAAGTTCAGCCAGTATATGAAATTGGATA
TTGCAGCAGTCAGAGCCCTTAACCTTTTTCAG (SEQ ID NO:125)
gtaaaaaaaaaaaaaaaaaaaaa (SEQ ID NO:126)
aaaaggggttaaaaatgttgatt (SEQ ID NO:127)
gg
15 TTAAAAAATGTTT (SEQ ID NO:128)
t
caTTGACATATACTGAAGAAGCT (SEQ ID NO:129)
TATAAAGGAGCTAAAATATTTGGAAAT (SEQ ID NO:130)
att
20 ATTATACTTGGATTAGATAACTAGCTTTAAATGGGTGTATTTT (SEQ ID NO:131)

hMSH2 Exon 6

gtt
ttcactaatgagcttgccattc (SEQ ID NO:132)
tttctatttttattttttgtttactag (SEQ ID NO:133)
25 GGTTCTGTTGAAGATAACCACTGGCTCTCAGTCTCTGGCTGCCTTGCTGAATAAGTGTAA
AACCCCTCAAGGACAAAGACTTGTTAACCAGTGGATTAAGCAGCCTCTCATGGATAAGA
ACAGAATAGAGGAGAG (SEQ ID NO:134)
gtatgttattagtttataacttttcgtagttttatgtaacctgca (SEQ ID NO:135)
gttaccacacatgattatacc (SEQ ID NO:136)
30 ac

hMSH2 Exon 7

ga

cttacgtgcttagttgataa (SEQ ID NO:137)

atTTtaattttataactaaaatattttacattaattcaagttaattttatttcag (SEQ ID
5 NO:138)

ATTGAATTTAGTGGAAGCTTTTGTAGAAGATGCAGAATTGAGGCAGACTTTACAAGAAG
ATTTACTTCGTCGATTCCCAGATCTTAACCGACTTGCCAAGAAGTTTCAAAGACAAGCA
GCAAACTTACAAGATTGTTACCGACTCTATCAGGGTATAAATCAACTACCTAATGTTAT
ACAGGCTCTGGAAAAACATGAAG (SEQ ID NO:139)

10 gtaacaagtgatttttgttttttttg (SEQ ID NO:140)

ttttccttcaactcatacaatata (SEQ ID NO:141)

tac

hMSH2 Exon 8

ga

15 tttgtattctgtaaaatgagatcttt (SEQ ID NO:142)

ttatttgtttggttttactacttttcttttag (SEQ ID NO:143)

GAAACACCAGAAATTATTGTTGGCAGTTTTTGTGACTCCTCTTACTGATCTTCGTTCT
GACTTCTCCAAGTTTCAGGAAATGATAGAAACAACCTTTAGATATGGATCAG (SEQ ID
NO:144)

20 gtatgcaatatacttttttaatttaag (SEQ ID NO:145)

cagtagttatttttaaaaagcaaag (SEQ ID NO:146)

gcc

hMSH2 Exon 9

gt

25 ctttacccattatttataggatt (SEQ ID NO:147)

ttgtcacttttggttctgtttgag (SEQ ID NO:148)

GTGGAAAACCATGAATTCCTTGTAACCTTCATTTGATCCTAATCTCAGTGAA
TTAAGAGAAATAATGAATGACTTGGAAGAAGATGCAGTCAACATTAATAAGTGCAGC
CAGAGATCTTG (SEQ ID NO:149)

30 gtaagaatgggtcattggag (SEQ ID NO:150)

gttgggaataattcttttgtctat (SEQ ID NO:151)

ac

hMSH2 Exon 10

gg

tagtaggtatattatggaataactttt (SEQ ID NO:152)

tcttttcttcttggtttatcaag (SEQ ID NO:153)

- 5 GCTTGGACCCTGGCAAACAGATTAAACTGGATTCCAGTGCACAGTTTGGATATTACTTTC
GTGTAACTGTAAAGGAAGAAAAAGTCCTTCGTAACAATAAAAACTTTAGTACTGTAGATA
TCCAGAAGAATGGTGTAAATTTACCAACAG (SEQ ID NO:154)
gtttgtaagtcattattatatttttaaccctttatt (SEQ ID NO:155)
aattccctaaatgctctaaca (SEQ ID NO:156)

10 tg

hMSH2 Exon 11

ca

cattgcttctagtacacattt (SEQ ID NO:157)

taatatttttaataaaaactggtatttcgatttgcag (SEQ ID NO:158)

- 15 CAAATTGACTTCTTTAAATGAAGAGTATACCAAAAATAAACAGAATATGAAGAAGCCC
AGGATGCCATTGTAAAGAAATTGTCAATATTTCTTCAG (SEQ ID NO:159)
gtaaacttaatagaactaa (SEQ ID NO:160)
taatgttctgaatgtcacctg (SEQ ID NO:161)

g

20 hMSH2 Exon 12

at

tcagtattcctgtgtacattt (SEQ ID NO:162)

tctgtttttatttttatacag (SEQ ID NO:163)

- GCTATGTAGAACCAATGCAGACACTCAATGATGTGTTAGCTCAGCTAGATGCTGTTGTC
25 AGCTTTGCTCACGTGTCAAATGGAGCACCTGTTCCATATGTACGACCAGCCATTTTGGAGAA
AGGACAAGGAAGAATTATATTAAGCATCCAGGCATGCTTGTGTTGAAGTTCAAGATG
AAATTGCATTTATTCCTAATGACGTATACTTTGAAAAAGATAAACAGATGTTCCACATC
ATTACTG (SEQ ID NO:164)
gtaaaaaacctggttt (SEQ ID NO:165)
30 ttggggctttgtgggggttaa (SEQ ID NO:166)
cg

hMSH2 Exon 13

cg

cgattaatcatcagtgtag (SEQ ID NO:167)

agtttaggactaacaatccatttatttagtagcagaaagaagtttaaaatcttgctttct

5 gatataatttggtttgtag (SEQ ID NO:168)

GCCCCAATATGGGAGGTAAATCAACATATATTGACAAACTGGGGTGATAGTACT

CATGGCCCAAATTGGGTGTTTTGTGCCATGTGAGTCAGCAGAAGTGTCCATTGTGGACTG

CATCTTAGCCCGAGTAGGGGCTGGTGACAGTCAATTGAAAGGAGTCTCCACGTTTCATGGC

TGAAATGTTGGAACTGCTTCTATCCTCAG (SEQ ID NO:169)

10 gtaagtgcacatctcctagtcctt (SEQ ID NO:170)

gaagatagaaatgtatgtctctg (SEQ ID NO:171)

tcc

hMSH2 Exon 14

ta

15 ccacattttatgtgatgggaa (SEQ ID NO:172)

atttcatgtaattatgtgcttcag (SEQ ID NO:173)

GTCTGCAACCAAAGATTCATTAATAATCATAGATGAATTGGGAAGAGGAACTTCTACCTA

CGATGGATTGTTGGTTAGCATGGGCTATATCAGAATACATTGCAACAAAGATTGGTGCTTT

TTGCATGTTTGCAACCCATTTTCATGAAGTACTGCCTTGGCCAATCAGATACCAACTGT

20 TAATAATCTACATGTCACAGCACTCACCCTGAAGAGACCTTAAGTATGCTTTATCAGGT

GAAGAAAG (SEQ ID NO:174)

gtatgtactattggagtactctaaattcagaacttg

gtaatgggaaacttactacc (SEQ ID NO:175)

cc

25 **hMSH2 Exon 15**

ct

cttctcatgctgtccctc (SEQ ID NO:176)

acgcttccccaaatttctttag (SEQ ID NO:177)

GTGTCTGTGATCAAAGTTTTGGGATTCATGTTGCAGAGCTTGCTAATTTCCCTAAGCAT

30 GTAATAGAGTGTGCTAAACAGAAAGCCCTGGAAGTTGAGGAGTTTCAGTATATTGGAGA

ATCGCAAGGATATGATATCATGGAACCAGCAGCAAAGAAGTGCTATCTGGAAAGAGAG

(SEQ ID NO:178)

gtttgtcagtttgtttt (SEQ ID NO:179)

catagttaaacttagcttctc (SEQ ID NO:180)

tat

hMSH2 Exon 16

ta

5 attactcatgggacattcaca (SEQ ID NO:181)

tgtgttttcag (SEQ ID NO:182)

CAAGGTGAAAAAATTATTTCAGGAGTTCCTGTCCAAGGTGAAACAAATGCCCTTTAC
TGAAATGTCAGAAGAAAACATCACATAAAGTTAAAACAGCTAAAAGCTGAAGTAATAGC
AAAGAATAATAGCTTTGTAAATGAAATCATTTACGAATAAAAGTTACTACGTGA (SEQ

10 ID NO:183)

aaa

atcccagtaatggaatgaag (SEQ ID NO:184)

gta

hMLH1 and hMSH2 genes were sequenced in 50 cancer
15 patients (age of onset <30) and 26 random anonymous donors.
Initial genomic sequencing detected 12 germline mutations in
12 patients (24%). Five mutations were found in hMLH1, and
7 in hMSH2. Using a combination of genomic sequencing and *in*
vitro synthesized-protein-truncation assay (IVSP), a total of
20 15 germ-line mutations were identified. The mutations are
described in Table 1.

Table 1: Pathogenic hMLH1 and hMSH2 Mutations Identified in Young Colorectal Cancer Probands

Gene and Patient	Mutation	Nucleotide Change	Effect on Coding Sequence	Location
hMLH1:				
329	616delAAG	Deletion of AAG at 1846-1848	Deletion of Lys616	Exon 16
533	IVS8-3delTA	Deletion of TA at 677-3	Splice mutation	IVS 8

5	696	K618A	AA→GC at 1852-1853	Lys→Ala at 618	Exon 16
	804	R659X	C→T at 1975	Arg→Stop at 659	Exon 17
	815	IVS1+1G→A	G→A at 116+1	Splice mutation	IVS 1
	817	del exon 13	Deletion of ~3 kb involving IVS 12 through exon 13 to IVS 13	Deletion of codons 470-520 (exon 13)	IVS 12-13, exon 13
	889		not identified	Truncation of IVSP	Exons 12-19
hMSH2:					
10	528	R406X	C→T at 1216	Arg→Stop at 406	Exon 7
	579	H639Y IVS13-1G→T	C→T at 1915 G→T at 2211	Double mutation results in deletion of codons 588-820 (exons 12-14)	Exon 12, IVS 13
	814	Q601X	C→T at 1801	Gln→Stop at 601	Exon 12
	818	Q252X	C→T at 754	Gln→Stop at 252	Exon 4
	825	delCTGT	Deletion of CTGT at 808-811	Deletion of codons 265-314 (exon 5)	Exon 5
	830	R680X	C→T at 2038	Arg→Stop at 680	Exon 13
	1157	M1L	A→T at 1	New initiation at codon 26	Exon 1

"IVS" means intervening sequence.

- 15 Two of the mutations identified in Table 1 for hMLH1 and three of the mutations identified in Table 1 for hMSH2 are believed

to be new. For hMLH1, these include: the splice mutation IVS1 + 1G-A in patient 815, also referred to herein as "hMLH1 mutant 1"; and deletion of exon 13 in patient 817, also referred to herein as "hMLH1 mutant 2". For hMSH2, these 5 include the double mutation H639Y IVS13-1G-T leading to deletion of codons 588-820 in patient 579, also referred to herein as "hMSH2 mutant 1", mutation R680X in patient 830 which comprises a nucleotide change from C to T at position 2038 in Exon 13 and results in a stop codon at position 680 10 of the coding sequence, also referred to herein as "hMSH2 mutant 2"; and mutation M1L in patient 1157 which comprises a nucleotide change from A to T at position 1 resulting in a new initiation at codon 26, also referred to herein as "hMSH2 mutant 3". Detection of these genetic mutations is useful in 15 diagnosing HNPCC in a patient and determining susceptibility of a patient for developing HNPCC.

There are several methodologies available from recombinant DNA technology which may be used for detecting these new variants and identifying additional genetic 20 mutations responsible for colon cancer. The identification of intronic sequences of hMLH1 and hMSH2 provided herein is particularly useful for design of intronic such as those exemplified in SEQ ID NO:1, 5, 7, 11, 12, 16, 17, 21, 23, 27, 28, 32, 33, 37, 38, 42, 43, 47, 48, 52, 53, 57, 58, 62, 63, 25 67, 68, 72, 73, 77, 78, 82, 83, 87, 88, 92, 93, 97, 100, 104, 105, 109, 111, 115, 117, 121, 123, 121, 123, 127, 129, 132, 136, 137, 141, 142, 146, 147, 151, 152, 156, 157, 161, 162, 166, 167, 171, 172, 175, 176, 180, 181 and 184 for use in identifying mutants in the splice donor or acceptor sites of 30 the hMLH1 or hMSH2 gene. Examples of methodologies useful in detecting and identifying new variants of these genes include, but are not limited to, direct probing, ligase chain reaction (LCR) and polymerase chain reaction (PCR) methodology.

Detection of variants or mutants using direct probing 35 involves the use of oligonucleotide probes which may be

prepared synthetically or by nick translation. In a preferred embodiment, the probes are complementary to at least a portion of the variant hMLH1 or hMSH2 genes identified herein. The DNA probes may be suitably labeled using, for example, a radiolabel, enzyme label, fluorescent label, or biotin-avidin label, for subsequent visualization in for example a Southern blot hybridization procedure. The labeled probe is reacted with a sample of DNA from a patients suspected of having HNPCC bound to nitrocellulose or Nylon 66 substrate. The areas that carry DNA sequences complementary to the labeled DNA probe become labeled themselves as a consequence of the reannealing reaction. The areas of the filter that exhibit such labeling may then be visualized, for example, by autoradiography.

Alternative probe techniques, such as ligase chain reaction (LCR) involve the use of a mismatch probe, i.e., probes which have full complementarity with the target except at the point of the mutation or variation. The target sequence is then allowed to hybridize both with the oligonucleotides having full complementarity, i.e., oligonucleotides complementary to the hMLH1 or hMSH2 variants of the present invention, and oligonucleotides containing a mismatch under conditions which will distinguish between the two. By manipulating the reaction conditions, it is possible to obtain hybridization only where there is full complementarity. If a mismatch is present, then there is significantly reduced hybridization.

The polymerase chain reaction (PCR) is a technique that amplifies specific DNA sequences. Repeated cycles of denaturation, primer annealing and extension carried out with a heat stable enzyme Taq polymerase leads to exponential increases in the concentration of desired DNA sequences.

Given the knowledge of nucleotide sequences encoding the hMLH1 and hMSH2 genes, it is possible to prepare synthetic oligonucleotides complementary to the sequences which flank the DNA of interest. Each oligonucleotide is complementary

to one of the two strands. The DNA is then denatured at high temperatures (e.g., 95°C) and then reannealed in the presence of a large molar excess of oligonucleotides. The oligonucleotides, oriented with their 3' ends pointing towards
5 each other, hybridize to opposite strands of the target sequence and prime enzymatic extension along the nucleic acid template in the presence of the four deoxyribonucleotide triphosphates. The end product is then denatured again for another cycle. After this three-step cycle has been repeated
10 several times, amplification of a DNA segment by more than one million fold can be achieved. The resulting DNA may then be directly sequenced in order to locate any genetic alterations. Alternatively, the identified hMLH1 and hMSH2 variants of the present invention make it possible to prepare oligonucleotides
15 that will only bind to altered DNA, so that PCR will only result in the multiplication of the DNA if the mutation is present. Following PCR, allele-specific oligonucleotide hybridization may be used to detect the colon cancer point mutation.

20 Alternatively, an adaptation of PCR called amplification of specific alleles (PASA) can be employed; this method uses differential amplification for rapid and reliable distinction between alleles that differ at a single base pair. Newton et al. Nucleic Acid Res. 1989 17:2503; Nichols et al. Genomics
25 1989 5:535; Okayama et al. J. Lab. Clin. Med. 1989 1214:105; Sarkar et al. Anal. Biochem. 1990 186:64; Sommer et al. Mayo Clin. Proc. 1989 64:1361; Wu, Proc. Nat'l Acad. Sci. USA 1989 86:2757; and Dutton et al. Biotechniques 1991 11:700. PASA involves amplification with two oligonucleotide primers such
30 that one is allele specific. The desired allele is efficiently amplified, while the other allele(s) is poorly amplified because it mismatches with a base at or near the 3' end of the allele specific primer. Thus, PASA or the related method PAMSA can be used to specifically amplify one or more
35 mutant hMLH1 or hMSH2 alleles. Where such amplification is

performed on genetic material obtained from a patient, it can serve as a method of detecting the presence of one or more mutant hMLH1 and/or hMSH2 alleles in a patient. PCR-induced mutation restriction analysis, often referred to as IMRA, can
5 also be used in the detection of mutants.

Also important is the development of experimental models of HNPCC. Such models can be used to screen for agents that alter the degenerative course of HNPCC. Having identified specific mutations in the hMLH1 and hMSH2 genes as a cause of
10 HNPCC, it is possible using genetic manipulation, to develop transgenic model systems and/or whole cell systems containing a mutated hMLH1 and/or hMSH2 gene or a portion thereof. The model systems can be used for screening drugs and evaluating the efficacy of drugs in treating HNPCC. In addition, these
15 model systems provide a tool for defining the underlying biochemistry of hMLH1 and hMSH2 and their relationship to HNPCC, thereby providing a basis for rational drug design.

One type of cell system which can be used in the present invention can be naturally derived. For this, blood samples
20 from an affected individual are obtained and permanently transformed into a lymphoblastoid cell line using, for example, Epstein-Barr virus. Once established, such cell lines can be grown continuously in suspension cultures and can be used in a variety of *in vitro* experiments to study hMLH1
25 and hMSH2 expression and processing. Another cell line used in these studies comprises skin fibroblasts derived from patients.

The mutated gene can also be excised for use in the creation of transgenic animals containing the mutated gene.
30 For example, the hMLH1 and hMSH2 variants of the present invention can each be cloned and placed in a cloning vector. Examples of cloning vectors which can be used include, but are not limited to, lCharon35, cosmid, or yeast artificial chromosome. The variant hMLH1 or hMSH2 gene can then be
35 transferred to a host nonhuman knockout animal such as a

knockout mouse. As a result of the transfer, the resultant transgenic nonhuman animal will preferably express one or more of the variant hMLH1 or hMSH2 polypeptides.

Alternatively, minigenes encoding variant hMLH1 or hMSH2 polypeptides can be designed. Such minigenes may contain a cDNA sequence encoding a variant hMLH1 or hMSH2 polypeptide, preferably full-length, a combination of hMLH1 or hMSH2 exons, or a combination thereof, linked to a downstream polyadenylation signal sequence and an upstream promoter (and preferably enhancer). Such a minigene construct will, when introduced into an appropriate transgenic host, such as a mouse or rat, express a variant hMLH1 or hMSH2 polypeptide.

One approach to creating transgenic animals is to target a mutation to the desired gene by homologous recombination in an embryonic stem (ES) cell *in vitro* followed by microinjection of the modified ES cell line into a host blastocyst and subsequent incubation in a foster mother. Frohman et al. Cell 1989 56:145. Alternatively, the technique of microinjection of the mutated gene, or portion thereof, into a one-cell embryo followed by incubation in a foster mother can be used. Additional methods for producing transgenic animals are well known in the art.

Transgenic animals are used in the assessment of new therapeutic compositions and in carcinogenicity testing, as exemplified by U.S. Patent 5,223,610. These animals are also used in the development of predictive animal models for human disease states, as exemplified in U.S. Patent 5,221,778. Therefore, the novel mutations of the hMLH1 and hMSH2 genes of the present invention, which are believed to cause HNPCC, provide a useful means for developing knockout transgenic animals to assess this disease.

Site directed mutagenesis and/or gene conversion can also be used to a mutate a non human hMLH1 or hMSH2 gene allele, either endogenously or via transfection, such that the

mutated gene encodes a polypeptide with an altered amino acid as described in the present invention.

In addition, antibodies to the hMLH1 or hMSH2 gene and variants thereof can be raised for use in the examination of the function of the truncated transcripts of the hMLH1 or hMSH2 gene. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

Antibodies generated against the hMLH1 and hMSH2 genes of the present invention can be obtained by direct injection into an animal or by administering the gene to an animal, preferably a nonhuman. The antibody so obtained will then bind the hMLH1 or hMSH2 gene or itself. In this manner, even a fragment of the gene can be used to generate these antibodies.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler et al. Nature 1975 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al. Immunology Today 1983 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., 1985, pp. 77-96).

Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to the hMLH1 or hMSH2 genes of this invention. Also, transgenic mice may be used to express humanized antibodies to the hMLH1 or hMSH2 genes of this invention.

The following nonlimiting examples are provided to further illustrate the present invention.

EXAMPLES**Example 1: Patients and Samples**

A total of 76 subjects were studied: 50 unrelated patients diagnosed with colorectal cancer at <30 years of age and 26 anonymous donors. There were 15 male and 11 female anonymous donors who were cancer free at the time of sampling and whose mean ages was 41 years. None of the study subjects were referred specifically because of a family history of colon cancer. All cancer patients had histologically confirmed colorectal cancer.

Peripheral blood was drawn from each subject and DNA was purified from peripheral-blood leukocytes.

Example 2: Genomic Sequencing

DNA was extracted from peripheral blood using the Nucleon DNA Extraction Kit, Scotlab, Lanarkshire, U.K. or using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN) as per the manufacturer's instructions. Each exon of hMSH2 and hMLH1 was amplified by PCR using 40 ng of genomic DNA in a volume of 50 μ L. Final reaction concentrations were 1 x PCR Buffer II (Perkin Elmer), 3.0 mM MgCl₂ (or 1.5 mM for hMSH2 exon 1), 0.2 mM dNTPs, 10 pmol of each specific oligonucleotide primer, and 1.25 units of Taq polymerase. Amplification was hot-started at 94°C for 3 minutes, followed by 35 cycles of 94°C for 20 seconds; 55°C for 20 seconds; 72°C for 40 seconds. The final reaction was extended at 72°C for 10 minutes, followed by storage at 4°C. Cycle sequencing used the PRISM Ready Dye Terminator Cycle Sequencing kit with AmpliTaq DNA polymerase, FS (Taq-FS; Perkin Elmer/Applied Biosystems) and an Applied Biosystems DNA Sequencer model 373A or 377 (Parker et al. BioTechniques 1996 21:694-699) according to the manufacturer's instructions. DNA sequence analysis was performed using Sequencher 3.0 (Gene Codes, Ann Arbor, MI) software by comparing published genomic sequences of hMLH1

(Han et al. Hum. Mol. Genet. 1995 4:237-242; Kolodner et al. Cancer Res. 1995 55:242-248) and hMSH2 (Kolodner, et al. Genomics 1994 24:516-526) with that of cancer cases or of random donors.

5 Examples of primers used for mutations in patients 815, 830 and 1157 are as follows:

(1) Patient 815, splice error in hMLH1 exon 1:

Forward primer:

5'-TGTAACACGACGGCCAGTCTGAGGTGATTGGCTGAAG-3' (SEQ ID NO:
10 185)

Reverse primer:

5'-GGAAACAGCTATGACCATGCCGTTAAGTCGTAGCCCTT-3' (SEQ ID NO:
186)

(2) Patient 830, premature stop codon in hMSH2 exon
15 13:

Forward primer:

5'-TGTAACACGACGGCCAGTCGATTAATCATCAGTGTAC-3' (SEQ ID NO:
187)

Reverse primer:

20 5'-GGAAACAGCTATGACCATGCAGAGACATACATTTCTATCTTC-3' (SEQ ID NO:
188)

(3) Patient 1157, missense in initial ATG of hMSH2
(exon 1):

Forward primer:

25 5'-TGTAACACGACGGCCAGTCGCATTTTCTTCAACCAGGA-3' (SEQ ID NO:
189)

Reverse primer:

5'-GGAAACAGCTATGACCATGCCTCCCCAGCACGCGCC-3' (SEQ ID NO: 190)

30 **Example 2: In Vitro Synthesized-Protein-Truncation
Assay (IVSP)**

cDNA was generated by reverse transcription of RNA purified from lymphoblastoid cell lines from the affected

index case. PCR amplification of the cDNA was used to introduce a 17-bp consensus T7 promoter sequence and a mammalian translation-initiation sequence in frame with a unique hMLH1 or hMSH2 sequence. PCR primer sequences and conditions were similar to those previously described in Example 1. Each gene was amplified in two or three overlapping segments. Resultant PCR products were used in a coupled transcription-translation reaction (Promega) incorporating 2-5 μ Ci of 35 S-methionine. Labeled in vitro-transcribed protein products from the reaction were heat denatured and were analyzed by use of 8%, 10% and 12% SDS-PAGE gels. Gels were washed in fixative and were autoradiographed overnight at room temperature. All samples showing truncated protein products were reamplified independently, and an additional IVSP analysis was performed for conformation. For each analysis, normal control samples were run in parallel, and the wild-type full length protein was noted. In most analyses, artifactual bands were visible, presumably due to internally initiated products since these were visible in samples from normal controls.

Example 3: Long Range PCR

For long range PCR of the novel mutation of hMSH2 discovered in patient 817, the GeneAmp XL PCR Kit (Perkin Elmer) was used with the following primers:

Forward primer:

5'-GGCCATTGTCACAGAGGATAAGA-3' (SEQ ID NO: 191)

Reverse primer:

5'-ACACAGCCCCACGAAGGAGTG-3' (SEQ ID NO: 192)

The reaction mixture contained about 400 ng of genomic DNA in a volume of 50 μ L. Final reaction concentrations were 1 x PCR Buffer II (Perkin Elmer), 1.5 mM $Mg(OAc)_2$, 0.8 mM dNTPs, 40 pmol of each specific oligonucleotide primer, and 4 units of rTth DNA polymerase. Amplification was hot-started at 94°C

for 1 minute, followed by 26 cycles of 94°C for 15 second and 68°C for 10 minutes. The final reaction was extended at 72°C for 10 minutes, followed by storage at 4°C.

Replicate cDNA sequencing of samples from patient 817 reproducibly demonstrated a truncation in hMSH2 due to deletion of the entire exon 13. However, extensive genomic sequencing failed to identify the mutation at the DNA level. Hence, the intronic region around exon 13 was analyzed by long range PCR to determine whether any large genomic deletion had completely removed that exon. Forward primer was in exon 12 and reverse in exon 14, giving around 15.5 kb wild type product. Using this approach, patient 817 was shown to carry a large deletion of approximately 3 kb which resulted in removal of exon 13.

Example 4: Characterization of mutation in patient 579

Characterization of the mutation in patient 579 was more complex. replicate hMSH2 IVSPs for patient 579 detected a very short protein fragment, which could not be explained on the basis of the His-Tyr mutation at codon 639, identified by genomic sequencing. Accordingly, additional genomic sequencing needed to be performed which resulted in identification of the second mutation at the splice acceptor site of exon 14. Using restriction-site changes induced by each mutation, both variants were traced through the family and were shown to reside on the same allele. Extensive sequencing of the reverse transcription-PCR products revealed that this complex double mutation results in an in-frame deletion of exons 12-14, thus accounting for the very short IVSP fragment. A His-Tyr mutation at codon 639 which results in a surrogate splice donor site and a 92-bp frameshift deletion of nucleotides 1914-2006, generating a premature termination codon 17 bp downstream of the exon 13 splice acceptor site has been described previously by Leach et al. Cell 1993 75:1215-1225 and Liu et al. Cancer Res. 1994

54:4590-4594. However, the 92 bp splice mutation reported to be present in this mutation was not present in patient 579, thus confirming that the double mutation in patient 579 is distinct from that reported by Liu et al. Cancer Res. 1994
5 54:4590-4594.

All publications including, but not limited to, patents and patent applications, cited in this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to
10 be incorporated by reference herein as though fully set forth.

The above description fully discloses the invention, including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further
15 elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore, the examples provided herein are to be construed as merely illustrative and are not a limitation of the scope of the present invention in any way.
20 The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

What is claimed is:

1. A variant human MLH1 or MSH2 gene comprising hMLH1 mutant 1, hMLH1 mutant 2, hMSH2 mutant 1, hMSH2 mutant 2 or hMSH2 mutant 3.
- 5 2. A method of diagnosing hereditary non-polyposis colorectal cancer in a patient comprising:
 - (a) obtaining a DNA sample from a patient; and
 - (b) screening the DNA sample for the variant human MLH1 or MSH2 gene of claim 1, wherein the presence of the variant
 - 10 gene is indicative of hereditary non-polyposis colorectal cancer.
3. A method for predicting susceptibility of a patient to developing hereditary non-polyposis colorectal cancer comprising:
 - 15 (a) obtaining a DNA sample from a patient; and
 - (b) screening the DNA sample for the variant human MLH1 or MSH2 gene of claim 1, wherein the presence of the variant gene is indicative of a susceptibility to hereditary non-polyposis colorectal cancer.
- 20 4. A method of identifying mutants in splice donor or acceptor sites of a human MLH1 gene comprising sequencing splice donor or acceptor sites of the human MLH1 gene with intronic primers for the human MLH1 gene and analyzing the sequences to identify any mutants.
- 25 5. An intronic primer for human MLH1.
6. A method of identifying mutants in splice donor or acceptor sites of a human MSH2 gene, comprising sequencing splice donor or acceptor sites of the human MSH2 gene with intronic primers for the human MSH2 gene and analyzing the
- 30 sequences to identify any mutants.

ABSTRACT

Variant human MLH1 and MSH2 genes are provided. Methods of using these variant genes to diagnose hereditary non-polyposis colorectal cancer (HNPCC) and/or determine a patient's susceptibility to developing HNPCC are also provided. Methods and compositions for identifying new variant MLH1 or MSH2 genes are also provided. In addition, experimental models for hereditary non-polyposis colorectal cancer comprising these variant genes are provided.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
22

Docket No.
DEX-0054

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL MUTATIONS IN HUMAN MLH1 AND HUMAN MSH2 GENES USEFUL IN DIAGNOSING COLORECTAL CANCER

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

October 22, 1998
(Filing Date)

(Filing Date)

(Filing Date)

(Filing Date)

(Filing Date)

(Filing Date)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Jane Massey Licata, Reg. No. 32,257

Kathleen A. Tyrrell, Reg. No. 38,350

Laura Plunkett, Reg. No. P45,015

of the firm

**Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, NJ 08053**

Send Correspondence to: **Jane Massey Licata
Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, NJ 08053**

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata Tel: 856-810-1515

Full name of sole or first inventor David Robbins	
Sole or first inventor's signature	Date
Residence Stevenson Ranch, California	
Citizenship US	
Post Office Address 26013 Baldwin Place	
Stevenson, Ranch, CA 91381	

Full name of second inventor, if any Juili Lillian Lin-Goerke	
Second inventor's signature	Date
Residence Spring City, Pennsylvania	
Citizenship Taiwan	
Post Office Address 135 Hill Church Road	
Spring City, PA 19475	

Full name of third inventor, if any Jessica C. Ling	
Third inventor's signature	Date
Residence Bensalem, Pennsylvania	
Citizenship US	
Post Office Address 735 Cliff Road	
Bensalem, PA 19020	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

SEQUENCE LISTING

<110> Robbins, David
Lin-Goerke, Juili L.
Ling, Jessica

<120> Novel Mutations in Human MLH1 and MSH2 Genes Useful in
Diagnosing Colorectal Cancer

<130> DEX-0054

<140>

<141>

<160> 192

<170> PatentIn Ver. 2.0

<210> 1

<211> 19

<212> DNA

<213> Homo sapiens

<400> 1

aggcactgag gtgattggc

19

<210> 2

<211> 54

<212> DNA

<213> Homo sapiens

<400> 2

tgaaggcact tccgttgagc atctagacgt ttccttggt cttctggcgc caaa

54

<210> 3

<211> 51

<212> DNA

<213> Homo sapiens

<400> 3

ggaagttatc cagcggccag ctaatgctat caaagagatg attgagaact g

51

<210> 4

<211> 21

<212> DNA

<213> Homo sapiens

<400> 4

gtacggaggg agtcgagccg g 21

<210> 5
 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 5
 gctcacttaa gggctacga 19

<210> 6
 <211> 8
 <212> DNA
 <213> Homo sapiens

<400> 6
 cttaacgg 8

<210> 7
 <211> 22
 <212> DNA
 <213> Homo sapiens

<400> 7
 aatatgtaca ttagagtagt tg 22

<210> 8
 <211> 35
 <212> DNA
 <213> Homo sapiens

<400> 8
 cagactgata aattatatttc tgtttgattt gccag 35

<210> 9
 <211> 91
 <212> DNA
 <213> Homo sapiens

<400> 9
 tttagatgca aaatccacaa gtattcaagt gattgttaaa gagggaggcc tgaagttgat 60
 tcagatccaa gacaatggca ccgggatcag g 91

<210> 10
 <211> 46
 <212> DNA
 <213> Homo sapiens

<400> 10
gtaagtaaaa cctcaaagta gcaggatggt tgtgcgcttc atggaa 46

<210> 11
<211> 19
<212> DNA
<213> Homo sapiens

<400> 11
gagtcaggac ctttctctg 19

<210> 12
<211> 22
<212> DNA
<213> Homo sapiens

<400> 12
agagatttgg aaaatgagta ac 22

<210> 13
<211> 34
<212> DNA
<213> Homo sapiens

<400> 13
atgattatctt actcatcttt ttggatatcta acag 34

<210> 14
<211> 99
<212> DNA
<213> Homo sapiens

<400> 14
aaagaagatc tggatattgt atgtgaaagg ttcactacta gtaaactgca gtcctttgag 60
gatttagcca gtatttctac ctatggcttt cgaggtgag 99

<210> 15
<211> 33
<212> DNA
<213> Homo sapiens

<400> 15
gtaagctaaa gattcaagaa atgtgtaaaa tat 33

<210> 16
<211> 19
<212> DNA
<213> Homo sapiens

<400> 16
 cctcctgtga tgacattgt 19

 <210> 17
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 17
 aacctttccc ttggtgagg 20

 <210> 18
 <211> 59
 <212> DNA
 <213> Homo sapiens

 <400> 18
 tgacagtggg tgaccagca gtgagttttt ctttcagtct attttctttt cttccttag 59

 <210> 19
 <211> 74
 <212> DNA
 <213> Homo sapiens

 <400> 19
 gctttggcca gcataagcca tgtgggtcat gttactatta caacgaaaac agctgatgga 60
 aagtgtgcat acag 74

 <210> 20
 <211> 53
 <212> DNA
 <213> Homo sapiens

 <400> 20
 gtatagtgtc gacttctttt actcatatat attcattctg aaatgtattt tgg 53

 <210> 21
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 21
 gcctaggtct cagagtaatc 20

 <210> 22
 <211> 7
 <212> DNA

<213> Homo sapiens

<400> 22

ttgatat

7

<210> 23

<211> 22

<212> DNA

<213> Homo sapiens

<400> 23

gattttctct tttccccttg gg

22

<210> 24

<211> 51

<212> DNA

<213> Homo sapiens

<400> 24

attagtatct atctctctac tggatattaa tttgttatat tttctcatta g

51

<210> 25

<211> 73

<212> DNA

<213> Homo sapiens

<400> 25

agcaagttac tcagatggaa aactgaaagc cctcctaaa ccatgtgctg gcaatcaagg 60
gaccagatc acg 73

<210> 26

<211> 21

<212> DNA

<213> Homo sapiens

<400> 26

gtaagaatgg tacatgggac a

21

<210> 27

<211> 23

<212> DNA

<213> Homo sapiens

<400> 27

gtaaattggt gaagctttgt ttg

23

<210> 28

<211> 26

<212> DNA

<213> Homo sapiens

<400> 28

gggttttatt ttcaagtact tctatg 26

<210> 29

<211> 31

<212> DNA

<213> Homo sapiens

<400> 29

aatttacaag aaaaatcaat cttctgttca g 31

<210> 30

<211> 92

<212> DNA

<213> Homo sapiens

<400> 30

gtggaggacc ttttttaca catagccacg aggagaaaag ctttaaaaaa tccaagtga 60
gaatatggga aaattttgga agttgttggc ag 92

<210> 31

<211> 61

<212> DNA

<213> Homo sapiens

<400> 31

gtacagtcca aaatctggga gtgggtctct gagatttgtc atcaaagtaa tgtgttctag 60
t 61

<210> 32

<211> 26

<212> DNA

<213> Homo sapiens

<400> 32

gtcatacat tgaacagttg ctgagc 26

<210> 33

<211> 18

<212> DNA

<213> Homo sapiens

<400> 33

ctagtgtgtg tttttggc 18

<210> 34
<211> 35
<212> DNA
<213> Homo sapiens

<400> 34
aactcttttc ttactctttt gtttttcttt tccag 35

<210> 35
<211> 43
<212> DNA
<213> Homo sapiens

<400> 35
gtattcagta cacaatgcag gcattagttt ctcagttaa aaa 43

<210> 36
<211> 70
<212> DNA
<213> Homo sapiens

<400> 36
gtaagttctt ggtttatggg ggatggtttt gttttatgaa aagaaaaaag gggattttta 60
atagtttgct 70

<210> 37
<211> 18
<212> DNA
<213> Homo sapiens

<400> 37
ggtggagata aggttatg 18

<210> 38
<211> 23
<212> DNA
<213> Homo sapiens

<400> 38
ctcagccatg agacaataaa tcc 23

<210> 39
<211> 27
<212> DNA
<213> Homo sapiens

<400> 39
ttgtgtcttc tgctgtttgt ttatcag 27

<210> 40
 <211> 89
 <212> DNA
 <213> Homo sapiens

 <400> 40
 caaggagaga cagtagctga tgtaggaca ctaccaatg cctcaaccgt ggacaatatt 60
 cgctccatct ttggaaatgc tgtagtcg 89

 <210> 41
 <211> 57
 <212> DNA
 <213> Homo sapiens

 <400> 41
 gtatgtcgat aacctatata aaaaaatctt ttacatttat tatcttggtt tatcatt 57

 <210> 42
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 42
 ccatcacatt atttggaac c 21

 <210> 43
 <211> 18
 <212> DNA
 <213> Homo sapiens

 <400> 43
 caaaagcttc agaatctc 18

 <210> 44
 <211> 11
 <212> DNA
 <213> Homo sapiens

 <400> 44
 ttttctaata g 11

 <210> 45
 <211> 113
 <212> DNA
 <213> Homo sapiens

 <400> 45

agaactgata gaaattggat gtgaggataa aaccctagcc ttcaaaatga atgggtacat 60
atccaatgca aactactcag tgaagaagtg catcttctta ctcttcatca acc 113

<210> 46
<211> 28
<212> DNA
<213> Homo sapiens

<400> 46
gtaagttaaa aagaaccaca tgggaaat 28

<210> 47
<211> 23
<212> DNA
<213> Homo sapiens

<400> 47
ccactcacag gaaacaccca cag 23

<210> 48
<211> 24
<212> DNA
<213> Homo sapiens

<400> 48
catgactttg tgtgaatgta cacc 24

<210> 49
<211> 56
<212> DNA
<213> Homo sapiens

<400> 49
tgtgacctca cccctcagga cagttttgaa ctggttgctt tctttttatt gtttag 56

<210> 50
<211> 94
<212> DNA
<213> Homo sapiens

<400> 50
atcgtctggt agaatcaact tccttgagaa aagccataga aacagtgtat gcagcctatt 60
tgcccaaaaa cacacacca ttctgtacc tcag 94

<210> 51
<211> 41
<212> DNA
<213> Homo sapiens

<400> 51
gtaatgttagc accaaactcc tcaaccaaga ctcacaagga a 41

<210> 52
<211> 24
<212> DNA
<213> Homo sapiens

<400> 52
cagatgttct atcaggctct cctc 24

<210> 53
<211> 20
<212> DNA
<213> Homo sapiens

<400> 53
gggctttttc tccccctccc 20

<210> 54
<211> 39
<212> DNA
<213> Homo sapiens

<400> 54
actatctaag gtaattgttc tctcttattt tcctgacag 39

<210> 55
<211> 154
<212> DNA
<213> Homo sapiens

<400> 55
tttagaaatc agtccccaga atgtggatgt taatgtgcac cccacaaagc atgaagttca 60
cttcctgcac gaggagagca tcctggagcg ggtgcagcag cacatcgaga gcaagctcct 120
gggctccaat tcctccagga tgtacttcac ccag 154

<210> 56
<211> 58
<212> DNA
<213> Homo sapiens

<400> 56
gtcagggcgc ttctcatcca gctacttctc tggggccttt gaaatgtgcc cggccaga 58

<210> 57
<211> 18

<212> DNA
<213> Homo sapiens

<400> 57
cgtgagagcc cagatttt 18

<210> 58
<211> 19
<212> DNA
<213> Homo sapiens

<400> 58
aattatacct catactagc 19

<210> 59
<211> 116
<212> DNA
<213> Homo sapiens

<400> 59
ttctttctta gtactgctcc atttggggac ctgtatatct atacttctta ttctgagtct 60
ctccactata tatatatata tatatatatt tttttttttt ttttttttta atacag 116

<210> 60
<211> 371
<212> DNA
<213> Homo sapiens

<400> 60
actttgctac caggacttgc tggccctct ggggagatgg ttaaattccac aacaagtctg 60
acctcgtctt ctacttctgg aagtagtgat aagggtctatg cccaccagat gggttcgtaca 120
gattcccggg aacagaagct tgatgcattt ctgcagcctc tgagcaaacc cctgtccagt 180
cagccccagg ccattgtcac agaggataag acagatatatt ctagtggcag ggctaggcag 240
caagatgagg agatgcttga actcccagcc cctgctgaag tggctgccaa aaatcagagc 300
ttggaggggg atacaacaaa ggggacttca gaaatgtcag agaagagagg acctacttcc 360
agcaacccca g 371

<210> 61
<211> 29
<212> DNA
<213> Homo sapiens

<400> 61
gtatggcctt ttgggaaaag tacagccta 29

<210> 62
<211> 23
<212> DNA

<213> Homo sapiens

<400> 62

cctcctttat tctgtaataa aac

23

<210> 63

<211> 20

<212> DNA

<213> Homo sapiens

<400> 63

tgcaaccac aaaatttggc

20

<210> 64

<211> 53

<212> DNA

<213> Homo sapiens

<400> 64

taagtttaaa aacaagaata ataatgatct gcacttcctt ttcttcattg cag

53

<210> 65

<211> 149

<212> DNA

<213> Homo sapiens

<400> 65

aaagagacat cggaagatt ctgatgtgga aatggtggaa gatgattccc gaaaggaaat 60
gactgcagct tgtaccccc ggagaaggat cattaacct actagtgttt tgagtctcca 120
ggaagaaatt aatgagcagg gacatgagg 149

<210> 66

<211> 50

<212> DNA

<213> Homo sapiens

<400> 66

gtacgtaaac gctgtggcct gcctgggatg catagggcct caactgcca

50

<210> 67

<211> 20

<212> DNA

<213> Homo sapiens

<400> 67

ggtttttgaa atggagaaag

20

<210> 68

<211> 18
<212> DNA
<213> Homo sapiens

<400> 68
tgggtgtctct agttcttg 18

<210> 69
<211> 82
<212> DNA
<213> Homo sapiens

<400> 69
tgcctgggtgc tttgggtcaat gaagtggggg tggtaggatt ctattactta cctgtttttt 60
ggtttttattt tttgttttgc ag 82

<210> 70
<211> 109
<212> DNA
<213> Homo sapiens

<400> 70
ttctccggga gatgttgc ataccactcct tcgtgggctg tgtgaatcct cagtgggcct 60
tggcacagca tcaaaccaag ttataccttc tcaacaccac caagcttag 109

<210> 71
<211> 25
<212> DNA
<213> Homo sapiens

<400> 71
gtaaatcagc tgagtgtgtg aacaa 25

<210> 72
<211> 20
<212> DNA
<213> Homo sapiens

<400> 72
gcagagctac tacaacaatg 20

<210> 73
<211> 18
<212> DNA
<213> Homo sapiens

<400> 73
cccatttgtc ccaactgg 18

<210> 74
<211> 57
<212> DNA
<213> Homo sapiens

<400> 74
ttgtatctca agcatgaatt cagcttttcc ttaaagtcac ttcattttta ttttcag 57

<210> 75
<211> 64
<212> DNA
<213> Homo sapiens

<400> 75
tgaagaactg ttctaccaga tactcattta tgattttgcc aattttggtg ttctcaggtt 60
atcg 64

<210> 76
<211> 23
<212> DNA
<213> Homo sapiens

<400> 76
gtaagtttag atccttttca ctt 23

<210> 77
<211> 19
<212> DNA
<213> Homo sapiens

<400> 77
ctgacatttc aactgaccg 19

<210> 78
<211> 22
<212> DNA
<213> Homo sapiens

<400> 78
catttgatg ctccgttaaa gc 22

<210> 79
<211> 30
<212> DNA
<213> Homo sapiens

<400> 79

ttgtctcttc atgttcttgc ttcttcctag

30

<210> 80
<211> 165
<212> DNA
<213> Homo sapiens

<400> 80
gagccagcac cgctctttga ccttgccatg cttgccttag atagtccaga gagggtgg 60
acagaggaag atgggtccaa agaaggactt gctgaatata ttgttgagtt tctgaagaag 120
aaggctgaga tgcttgcaga ctatttctct ttggaaattg atgag 165

<210> 81
<211> 36
<212> DNA
<213> Homo sapiens

<400> 81
gtgtgacagc cattcttata cttctgttgt attctc 36

<210> 82
<211> 23
<212> DNA
<213> Homo sapiens

<400> 82
caaataaaat ttccagccgg gtg 23

<210> 83
<211> 22
<212> DNA
<213> Homo sapiens

<400> 83
ggaaaggcac tggagaaatg gg 22

<210> 84
<211> 59
<212> DNA
<213> Homo sapiens

<400> 84
atttgtttaa actatgacag cattatttct tgttcccttg tcctttttcc tgcaagcag 59

<210> 85
<211> 93
<212> DNA
<213> Homo sapiens

<400> 85
gaaggggaacc tgattggatt accccttctg attgacaact atgtgcccc tttggagggg 60
ctgcctatct tcattcttcg actagccact gag 93

<210> 86
<211> 29
<212> DNA
<213> Homo sapiens

<400> 86
gtcagtgatc aagcagatac taagcattt 29

<210> 87
<211> 25
<212> DNA
<213> Homo sapiens

<400> 87
cggtagatgc atgtgtgctg gaggg 25

<210> 88
<211> 20
<212> DNA
<213> Homo sapiens

<400> 88
taagtagtct gtgatctccg 20

<210> 89
<211> 60
<212> DNA
<213> Homo sapiens

<400> 89
tttagaatga gaatgtttaa attcgtacct attttgaggt attgaatttc tttggaccag 60

<210> 90
<211> 114
<212> DNA
<213> Homo sapiens

<400> 90
gtgaattggg acgaagaaaa ggaatgtttt gaaagcctca gtaaagaatg cgctatgttc 60
tattccatcc ggaagcagta catatctgag gagtcgaccc tctcaggcca gcag 114

<210> 91
<211> 35

<212> DNA
<213> Homo sapiens

<400> 91
gtacagtggg gatgcacact ggcaccccag gacta 35

<210> 92
<211> 18
<212> DNA
<213> Homo sapiens

<400> 92
ggacaggacc tcatacat 18

<210> 93
<211> 18
<212> DNA
<213> Homo sapiens

<400> 93
gacaccagtg tatgttgg 18

<210> 94
<211> 42
<212> DNA
<213> Homo sapiens

<400> 94
gatgcaaaca gggaggctta tgacatctaa tgtgttttcc ag 42

<210> 95
<211> 168
<212> DNA
<213> Homo sapiens

<400> 95
agtgaagtgc ctggctccat tccaaactcc tggaagtgga ctgtggaaca cattgtctat 60
aaagccttgc gctcacacat tctgcctcct aaacatttca cagaagatgg aaatatcctg 120
cagcttgcta acctgcctga tctatacaaa gtctttgaga ggtgttaa 168

<210> 96
<211> 21
<212> DNA
<213> Homo sapiens

<400> 96
atatggttat ttatgcactg t 21

<210> 97
<211> 20
<212> DNA
<213> Homo sapiens

<400> 97
gggatgtgtt cttctttctc 20

<210> 98
<211> 60
<212> DNA
<213> Homo sapiens

<400> 98
tgtattccga tacaaaagtgt tgtatcaaag tgtgatatac aaagtgtacc aacataagtg 60

<210> 99
<211> 31
<212> DNA
<213> Homo sapiens

<400> 99
ggcgggaaac agcttagtgg gtgtggggtc g 31

<210> 100
<211> 20
<212> DNA
<213> Homo sapiens

<400> 100
cgcattttct tcaaccagga 20

<210> 101
<211> 17
<212> DNA
<213> Homo sapiens

<400> 101
ggtgaggagg tttcgac 17

<210> 102
<211> 211
<212> DNA
<213> Homo sapiens

<400> 102
atggcggtgc agccgaagga gacgctgcag ttggagagcg cggccgaggt cggcttcgtg 60
cgcttctttc agggcatgcc ggagaagccg accaccacag tgcgcctttt cgaccggggc 120

gacttctata cggcgacagg cgaggacgag ctgctggccg cccgggaggt gttcaagacc 180
caggggggtga tcaagtacat ggggcccggca g 211

<210> 103
<211> 14
<212> DNA
<213> Homo sapiens

<400> 103
gtgagggccg ggac 14

<210> 104
<211> 17
<212> DNA
<213> Homo sapiens

<400> 104
ggcgcgtgct ggggagg 17

<210> 105
<211> 21
<212> DNA
<213> Homo sapiens

<400> 105
gtccagctaa tacagtgctt g 21

<210> 106
<211> 46
<212> DNA
<213> Homo sapiens

<400> 106
aacatgtaat atctcaaatc tgtaatgtac tttttttttt ttttaag 46

<210> 107
<211> 155
<212> DNA
<213> Homo sapiens

<400> 107
gagcaaagaa tctgcagagt gttgtgctta gtaaaatgaa ttttgaatct tttgtaaaag 60
atcttcttct gggttcgtcag tatagagttg aagtttataa gaatagagct ggaaataagg 120
catccaagga gaatgattgg tatttgcat ataag 155

<210> 108
<211> 33
<212> DNA

<213> Homo sapiens

<400> 108

gtaattatct tccttttttaa tttacttatt ttt

33

<210> 109

<211> 25

<212> DNA

<213> Homo sapiens

<400> 109

ttaagagtag aaaaataaaa atgtg

25

<210> 110

<211> 32

<212> DNA

<213> Homo sapiens

<400> 110

attaataagg ttcataagagt ttggattttt cc

32

<210> 111

<211> 26

<212> DNA

<213> Homo sapiens

<400> 111

ttataaaatt ttaaagtatg ttcaag

26

<210> 112

<211> 36

<212> DNA

<213> Homo sapiens

<400> 112

agtttgtaa atttttaaaa ttttattttt acttag

36

<210> 113

<211> 279

<212> DNA

<213> Homo sapiens

<400> 113

gcttctcctg gcaatctctc tcagtttgaa gacattctct ttggtaacaa tgatatgtca 60
gcttccattg gtgttggtggg tgtaaaaatg tccgcagttg atggccagag acaggttgga 120
gttgggtatg tggattccat acagaggaaa ctaggactgt gtgaattccc tgataatgat 180
cagttctcca atcttgaggc tctcctcatc cagattggac caaaggaatg tgttttaccc 240
ggaggagaga ctgctggaga catggggaaa ctgagacag 279

<210> 114
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 114
 gtaagcaaatt tgagtctagt gat 23

 <210> 115
 <211> 25
 <212> DNA
 <213> Homo sapiens

 <400> 115
 agaggagatt ccaggcctag gaaag 25

 <210> 116
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 116
 tctttaattg acatgatact g 21

 <210> 117
 <211> 24
 <212> DNA
 <213> Homo sapiens

 <400> 117
 tttttgcttt tcttattcct tttc 24

 <210> 118
 <211> 33
 <212> DNA
 <213> Homo sapiens

 <400> 118
 tcatagtagt ttaaactatt tctttcaaaa tag 33

 <210> 119
 <211> 147
 <212> DNA
 <213> Homo sapiens

 <400> 119
 ataattcaaa gaggaggaat tctgatcaca gaaagaaaaa aagctgactt ttccacaaaa 60

gacatttatc aggacctcaa ccggttggtg aaaggcaaaa agggagagca gatgaatagt 120
gctgtattgc cagaaatgga gaatcag 147

<210> 120
<211> 85
<212> DNA
<213> Homo sapiens

<400> 120
gtacatggat tataaatgtg aattacaata tatataatgt aaatatgtaa tatataataa 60
ataatatgta aactatagtg actttt 85

<210> 121
<211> 20
<212> DNA
<213> Homo sapiens

<400> 121
ttagaaggat atttctgtca 20

<210> 122
<211> 10
<212> DNA
<213> Homo sapiens

<400> 122
actggcacca 10

<210> 123
<211> 24
<212> DNA
<213> Homo sapiens

<400> 123
gtggtataga aatcttcgat tttt 24

<210> 124
<211> 16
<212> DNA
<213> Homo sapiens

<400> 124
aaattcttaa ttttag 16

<210> 125
<211> 150
<212> DNA
<213> Homo sapiens

<400> 125
gttgacagttt catcactgtc tgcggtaatc aagtttttag aactcttata agatgattcc 60
aactttggac agtttgaact gactactttt gacttcagcc agtatatgaa attggatatt 120
gcagcagtc gagcccttaa cctttttcag 150

<210> 126
<211> 23
<212> DNA
<213> Homo sapiens

<400> 126
gtaaaaaaaa aaaaaaaaaa aaa 23

<210> 127
<211> 22
<212> DNA
<213> Homo sapiens

<400> 127
aaaagggtta aaaatgttga tt 22

<210> 128
<211> 13
<212> DNA
<213> Homo sapiens

<400> 128
ttaaaaaatg ttt 13

<210> 129
<211> 23
<212> DNA
<213> Homo sapiens

<400> 129
cattgacata tactgaagaa gct 23

<210> 130
<211> 27
<212> DNA
<213> Homo sapiens

<400> 130
tataaaggag ctaaaatatt tggaat 27

<210> 131
<211> 43

<212> DNA
 <213> Homo sapiens

 <400> 131
 attatacttg gattagataa ctagctttaa atgggtgtat ttt 43

 <210> 132
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 132
 ttcactaatg agcttgccat tc 22

 <210> 133
 <211> 26
 <212> DNA
 <213> Homo sapiens

 <400> 133
 tttctatattt attttttgtt tactag 26

 <210> 134
 <211> 134
 <212> DNA
 <213> Homo sapiens

 <400> 134
 ggttctgttg aagataccac tggtctcag tctctggctg ccttgctgaa taagtgtaaa 60
 acccctcaag gacaaagact tgtaaccag tggattaagc agcctctcat ggataagaac 120
 agaatagagg agag 134

 <210> 135
 <211> 44
 <212> DNA
 <213> Homo sapiens

 <400> 135
 gtatgttatt agtttatact ttcgttagtt ttatgtaacc tgca 44

 <210> 136
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 136
 gttaccaca tgattatacc 20

<210> 137
<211> 20
<212> DNA
<213> Homo sapiens

<400> 137
cttacgtgct tagttgataa 20

<210> 138
<211> 53
<212> DNA
<213> Homo sapiens

<400> 138
attttaattt tataactaaaa tattttacat taattcaagt taatttattt cag 53

<210> 139
<211> 200
<212> DNA
<213> Homo sapiens

<400> 139
attgaattta gtggaagctt ttgtagaaga tgcagaattg aggcagactt tacaagaaga 60
tttacttcgt cgattcccag atcttaaccg acttgccaag aagtttcaaa gacaagcagc 120
aaacttacaa gattgttacc gactctatca gggataaat caactaccta atgttatata 180
ggctctggaa aaacatgaag 200

<210> 140
<211> 24
<212> DNA
<213> Homo sapiens

<400> 140
gtaacaagtg attttgtttt ttg 24

<210> 141
<211> 24
<212> DNA
<213> Homo sapiens

<400> 141
ttttccttca actcatacaa tata 24

<210> 142
<211> 26
<212> DNA
<213> Homo sapiens

<400> 142
tttgtattct gtaaaatgag atcttt 26

<210> 143
<211> 30
<212> DNA
<213> Homo sapiens

<400> 143
ttatttggtt gttttactac tttcttttag 30

<210> 144
<211> 110
<212> DNA
<213> Homo sapiens

<400> 144
gaaaacacca gaaattattg ttggcagttt ttgtgactcc tcttactgat cttcgttctg 60
acttctccaa gtttcaggaa atgatagaaa caactttaga tatggatcag 110

<210> 145
<211> 26
<212> DNA
<213> Homo sapiens

<400> 145
gtatgcaata tactttttaa ttttaag 26

<210> 146
<211> 25
<212> DNA
<213> Homo sapiens

<400> 146
cagtagttat ttttaaaaag caaag 25

<210> 147
<211> 23
<212> DNA
<213> Homo sapiens

<400> 147
ctttacccat tatttatagg att 23

<210> 148
<211> 23
<212> DNA
<213> Homo sapiens

<400> 148
ttgtcacttt gttctgtttg cag 23

<210> 149
<211> 124
<212> DNA
<213> Homo sapiens

<400> 149
gtggaaaacc atgaattcct tgtaaaacct tcatttgatc ctaatctcag tgaattaaga 60
gaaataatga atgacttgga aaagaagatg cagtcaacat taataagtgc agccagagat 120
cttg 124

<210> 150
<211> 20
<212> DNA
<213> Homo sapiens

<400> 150
gtaagaatgg gtcattggag 20

<210> 151
<211> 23
<212> DNA
<213> Homo sapiens

<400> 151
gttgggaataa ttcttttgtc tat 23

<210> 152
<211> 25
<212> DNA
<213> Homo sapiens

<400> 152
tagtaggtat ttatggaata ctttt 25

<210> 153
<211> 22
<212> DNA
<213> Homo sapiens

<400> 153
tcttttcttc ttgtttatca ag 22

<210> 154
<211> 151

<212> DNA
<213> Homo sapiens

<400> 154
gcttggaccc tggcaaacag attaaactgg attccagtgc acagtttgga tattactttc 60
gtgtaacctg taaggaagaa aaagtccttc gtaacaataa aaacttttagt actgtagata 120
tccagaagaa tgggtgtaaa tttaccaaca g 151

<210> 155
<211> 36
<212> DNA
<213> Homo sapiens

<400> 155
gtttgtaagt cattattata tttttaaccc tttatt 36

<210> 156
<211> 21
<212> DNA
<213> Homo sapiens

<400> 156
aattccctaa atgctctaac a 21

<210> 157
<211> 21
<212> DNA
<213> Homo sapiens

<400> 157
cattgcttct agtacacatt t 21

<210> 158
<211> 36
<212> DNA
<213> Homo sapiens

<400> 158
taatattttt aataaaaactg ttatttcgat ttgcag 36

<210> 159
<211> 98
<212> DNA
<213> Homo sapiens

<400> 159
caaattgact tcttttaaatg aagagtatac caaaaataaa acagaatatg aagaagccca 60
ggatgccatt gttaaagaaa ttgtcaatat ttcttcag 98

<210> 160
 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 160
 gtaaaacttaa tagaactaa 19

<210> 161
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 161
 taatgttctg aatgtcacct g 21

<210> 162
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 162
 tcagtattcc tgtgtacatt t 21

<210> 163
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 163
 tctgttttta tttttataca g 21

<210> 164
 <211> 246
 <212> DNA
 <213> Homo sapiens

<400> 164
 gctatgtaga accaatgcag acactcaatg atgtgttagc tcagctagat gctgttgtca 60
 gctttgctca cgtgtcaa at ggagcacctg ttccatatgt acgaccagcc attttgagaga 120
 aaggacaagg aagaattata ttaaaagcat ccaggcatgc ttgtgttgaa gttcaagatg 180
 aaattgcatt tattccta at gacgtatact ttgaaaaaga taaacagatg ttccacatca 240
 ttactg 246

<210> 165
 <211> 16
 <212> DNA

<213> Homo sapiens

<400> 165

gtaaaaaacc tggttt

16

<210> 166

<211> 19

<212> DNA

<213> Homo sapiens

<400> 166

ttgggctttg tgggggtaa

19

<210> 167

<211> 19

<212> DNA

<213> Homo sapiens

<400> 167

cgattaatca tcagtgtac

19

<210> 168

<211> 78

<212> DNA

<213> Homo sapiens

<400> 168

agtttaggac taacaatcca tttattagta gcagaaagaa gtttaaaatc ttgctttctg 60
atataatttg ttttgtag 78

<210> 169

<211> 205

<212> DNA

<213> Homo sapiens

<400> 169

gccccaatat gggaggtaaa tcaacatata ttcgacaaac tggggtgata gtactcatgg 60
cccaaattgg gtgttttgtg ccatgtgagt cagcagaagt gtccattgtg gactgcatct 120
tagcccgagt aggggctggt gacagtcaat tgaaaggagt ctccacgttc atggctgaaa 180
tgttggaaac tgcttctatc ctcag 205

<210> 170

<211> 23

<212> DNA

<213> Homo sapiens

<400> 170

gtaagtgcac ctccatgtcc ctt

23

<210> 171
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 171
 gaagatagaa atgtatgtct ctg 23

<210> 172
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 172
 ccacatttta tgtgatggga a 21

<210> 173
 <211> 24
 <212> DNA
 <213> Homo sapiens

<400> 173
 atttcattgta attatgtgct tcag 24

<210> 174
 <211> 248
 <212> DNA
 <213> Homo sapiens

<400> 174
 gtctgcaacc aaagattcat taataatcat agatgaattg ggaagaggaa cttctaccta 60
 cgatggattt gggtttagcat gggctatatc agaatacatt gcaacaaaga ttggtgcttt 120
 ttgcatgttt gcaaccatt ttcattgaact tactgccttg gccaatcaga taccaactgt 180
 taataatcta catgtcacag cactcaccac tgaagagacc ttaactatgc tttatcaggt 240
 gaagaaag 248

<210> 175
 <211> 56
 <212> DNA
 <213> Homo sapiens

<400> 175
 gtatgtacta ttggagtact ctaaattcag aacttggttaa tgggaaactt actacc 56

<210> 176
 <211> 19
 <212> DNA

<213> Homo sapiens

<400> 176

cttctcatgc tgtcccctc

19

<210> 177

<211> 23

<212> DNA

<213> Homo sapiens

<400> 177

acgcttcccc aaatttctta tag

23

<210> 178

<211> 176

<212> DNA

<213> Homo sapiens

<400> 178

gtgtctgtga tcaaagtttt gggattcatg ttgcagagct tgctaatttc cctaagcatg 60
taatagagtg tgctaaacag aaagccctgg aacttgagga gtttcagtat attggagaat 120
cgcaaggata tgatatcatg gaaccagcag caaagaagtg ctatctggaa agagag 176

<210> 179

<211> 17

<212> DNA

<213> Homo sapiens

<400> 179

gtttgtcagt ttgtttt

17

<210> 180

<211> 21

<212> DNA

<213> Homo sapiens

<400> 180

catagtttaa cttagcttct c

21

<210> 181

<211> 21

<212> DNA

<213> Homo sapiens

<400> 181

attactcatg ggacattcac a

21

<210> 182

<211> 10
<212> DNA
<213> Homo sapiens

<400> 182
tgtgttttcag 10

<210> 183
<211> 171
<212> DNA
<213> Homo sapiens

<400> 183
caaggtgaaa aaattattca ggagttcctg tccaaggtga aacaaatgcc ctttactgaa 60
atgtcagaag aaaacatcac aataaagtta aaacagctaa aagctgaagt aatagcaaag 120
aataatagct ttgtaaatga aatcatttca cgaataaaaag ttactacgtg a 171

<210> 184
<211> 20
<212> DNA
<213> Homo sapiens

<400> 184
atcccagtaa tggaatgaag 20

<210> 185
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 185
tgtaaaacga cggccagtct gaggtgattg gctgaag 37

<210> 186
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 186
ggaaacagct atgaccatgc cgtaaagtcg tagccctt 38

<210> 187

<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 187
tgtaaaacga cggccagtcg attaatcatc agtgtac 37

<210> 188
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 188
ggaaacagct atgaccatgc agagacatac atttctatct tc 42

<210> 189
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 189
tgtaaaacga cggccagtcg cattttcttc aaccagga 38

<210> 190
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 190
ggaaacagct atgaccatgc ctccccagca cgcgcc 36

<210> 191
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 191

ggccattgtc acagaggata aga

23

<210> 192

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 192

acacagccca cgaaggagtg

20